



September 30, 2020

BSE Limited,
Department of Corporate Services,
P. J. Towers, Dalal Street,
Mumbai Samachar Marg,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Ltd.,**
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards launch of Lapatinib Tablets, 250 mg, after the Company's alliance partner Natco Pharma Ltd. received final approval for its ANDA from the U.S. FDA.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For LUPIN LIMITED

Rajvardh
an Vishnu
Satam

Digitally signed by Rajvardhan Vishnu Satam
DN: c=IN, o=Personal,
2.5.4.20=8a002ed6da3b7e41e01d
21c2b9062761a29a500491762a5ac5
49cb034cae, postalCode=400104,
sn=Maharashtra,
serialNumber=dfbe60a88c796663c
738ea258a0b475d195f726c0b67a2ff
09c424771b2a, cn=Rajvardhan
Vishnu Satam
Date: 2020.09.30 15:51:03 +05'30'

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl- : a/a.

Lupin Launches Lapatinib Tablets

Mumbai, Baltimore, September 30, 2020: Pharma major Lupin Limited (Lupin) announced today the launch of Lapatinib Tablets, 250 mg, after Lupin's alliance partner Natco Pharma Ltd received final approval for its ANDA from the United States Food and Drug Administration (U.S. FDA).

Lapatinib Tablets, 250 mg, are the generic equivalent of Tykerb® Tablets, 250 mg, of Novartis Pharmaceutical Corporation, and are indicated in combination with:

- Capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2), and who have received prior therapy including an anthracycline, a taxane and trastuzumab
- Letrozole for the treatment of postmenopausal women with hormone-receptor positive metastatic breast cancer that overexpresses the HER2 receptor, for whom hormonal therapy is indicated

Lapatinib Tablets (RLD: Tykerb®) had annual sales of approximately USD 61 million in the U.S. (IQVIA MAT June 2020).

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the 3rd largest pharmaceutical company in the U.S. by prescriptions and 5th in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/

Facebook: www.facebook.com/LupinWorld/

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

For further information or queries please contact –

Arvind Bothra

Head – Investor Relations and Corporate Communications

Email: arvindbothra@lupin.com

Tel: +91 22 6640 8237

Manjira Sharma

General Manager – Corporate Communications

Email: manjirasharma@lupin.com

Tel: +91 22 6640 2532

*[*Safe Harbor Statement](#)*

Tykerb® is a registered trademark of Novartis Pharma AG